Aesthetic plastic surgery · 2026
Systemic Tacrolimus Attenuates Peri-Implant Capsule Formation and Inflammatory/Fibrotic Signaling in a Rat Silicone Implant Model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Hyung Bae, Lee Nara, Han Hyun Ho, Eom Jin Sup
Аннотация
BACKGROUND: Capsule formation in contact with silicone implants may vary according to the administration of systemic immunosuppressive drugs.
METHODS: A total of 18 Sprague-Dawley rats that underwent premuscular plane silicone implant insertion were divided into three groups as follows: Group 1, untreated negative control (n = 6); Group 2, treated with tacrolimus (n = 6); and Group 3, treated with dexamethasone as a positive control (n = 6). At 3 months after surgery, the histology and immunochemistry of the capsule tissues were analyzed.
RESULTS: Systemic administration of dexamethasone and tacrolimus successfully reduced capsule thickness and inflammatory marker levels. The aggregation of CD3 (T lymphocytes)- and CD68 (histiocytes)-positive cells around the capsule also reduced.
CONCLUSIONS: This study aimed to evaluate whether systemic immunosuppression with tacrolimus modulates peri-implant capsule formation and key inflammatory/fibrotic pathways in a rat silicone implant model. We focused on histologic capsule thickness and immunohistochemical markers representing innate/adaptive immune activation and myofibroblast-driven fibrosis as surrogate measures of early periprosthetic tissue remodeling.
NO LEVEL ASSIGNED: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
METHODS: A total of 18 Sprague-Dawley rats that underwent premuscular plane silicone implant insertion were divided into three groups as follows: Group 1, untreated negative control (n = 6); Group 2, treated with tacrolimus (n = 6); and Group 3, treated with dexamethasone as a positive control (n = 6). At 3 months after surgery, the histology and immunochemistry of the capsule tissues were analyzed.
RESULTS: Systemic administration of dexamethasone and tacrolimus successfully reduced capsule thickness and inflammatory marker levels. The aggregation of CD3 (T lymphocytes)- and CD68 (histiocytes)-positive cells around the capsule also reduced.
CONCLUSIONS: This study aimed to evaluate whether systemic immunosuppression with tacrolimus modulates peri-implant capsule formation and key inflammatory/fibrotic pathways in a rat silicone implant model. We focused on histologic capsule thickness and immunohistochemical markers representing innate/adaptive immune activation and myofibroblast-driven fibrosis as surrogate measures of early periprosthetic tissue remodeling.
NO LEVEL ASSIGNED: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .